CARD Trial TE - Results from #10

CARD Trial TE

Search

The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial -... Details William Oh and Stephen Freedland join Alicia Morgans to discuss the efficacy and safety in older patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide an analysis of the CARD Trial. Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively, with most deaths occurring in men over t...
The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC - Neal Shore Details Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer (mCRPC), that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment h...
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi Details In this discussion on the CARD trial with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from the ASCO GU 2020 presentation: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer from the CARD study. The objective of the QoL analysis was focused on three parti...
Clinical Implications of the CARD Trial - Cora Sternberg Details In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal Details Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...